MUC5AC and glioblastoma: Given MUC16 as a precedent for the clinical implementation of a mucin biomarker and growing evidence for mucin detection and association with outcomes in glioma, a careful evaluation of mucins as potential non-invasive precision biomarkers in GBM is indicated to help direct and interpret findings in this space.